HeartBeam Inc. Honored with 2025 Innovation Award for Revolutionary Remote Cardiac Diagnostics Technology

HeartBeam Inc. (NASDAQ: BEAT) has been awarded the 2025 Innovation Award in Remote Cardiac Diagnostics by the Medical Device Network Excellence Awards, recognizing its groundbreaking FDA-cleared 3D ECG technology. This technology enables clinical-grade arrhythmia diagnostics outside traditional clinical settings through a compact, cable-free device, representing a significant leap forward in cardiac care.

The award highlights the company's innovative approach to cardiac diagnostics, including its synthesized 12-lead ECG software, which is currently under FDA review. Upon receiving clearance, this technology is set for commercialization, further establishing HeartBeam's leadership in the remote cardiac care sector. The recognition adds to the company's growing list of accolades for its contributions to medical technology.

The implications of HeartBeam's achievement are profound, offering the potential to transform cardiac care by facilitating accurate diagnostics in non-clinical environments. This advancement could significantly improve patient access to timely cardiac assessments, reducing the reliance on hospital visits and enabling earlier detection of heart conditions. For more information on HeartBeam's innovative solutions, visit https://www.heartbeam.com.

HeartBeam's technology signifies a pivotal shift towards more accessible and efficient cardiac health management, promising to enhance patient outcomes globally. The company's continued focus on innovation and excellence in remote cardiac diagnostics underscores its commitment to advancing healthcare technology and improving lives.